GlycoBien®
INDICATION: Diabetes
GlycoBien® CR is a novel once-daily oral hypoglycemic drug for lowering blood sugar and reduction of glucose spikes.
![](https://orxpharmaceuticals.com/wp-content/uploads/2021/11/orx-glycobien-photo.png)
Discover GlycoBien®
![drug-overview drug-overview](https://orxpharmaceuticals.com/wp-content/uploads/2021/11/drug-overview-100x100.png)
Overview
GlycoBien® is designed to provide first-line therapy for both prediabetics and newly diagnosed Type 2 diabetic patients.
![drug-phase drug-phase](https://orxpharmaceuticals.com/wp-content/uploads/2021/11/drug-phase-100x100.png)
Phase
GlycoBien® CR is currently in Phase II clinical trial.
![drug-US-market drug-US-market](https://orxpharmaceuticals.com/wp-content/uploads/2021/11/drug-US-market-100x100.png)
US Market ($B USD)
The estimated market for GlycoBien® in the United States is $8 Billion USD.
![drug-global-market drug-global-market](https://orxpharmaceuticals.com/wp-content/uploads/2021/11/drug-global-market-100x100.png)
Global Market ($B USD)
The estimated market for GlycoBien® globally is $10 Billion USD.